Sensitizing effects and synergies were documented for combinations of MYB-targeting drugs with currently applied cancer therapeutics such as cisplatin, doxorubicin, and imatinib, which underline the potential of MYB inhibitors as promising anticancer drug candidates. The gene discussed is MYB; the disease is cancer.